Background The antihypertensive angiotensin receptor blockers (ARBs) and angiotensin-
converting enzyme inhibitors (ACE-Is) have similar indications and mechanisms of action …

Alzheimer's disease (AD) is a neurodegenerative disease, in which an accumulation of toxic
amyloid beta in the brain precedes the emergence of clinical symptoms. AD spectrum …

Background Recent studies on renin-angiotensin system (RAS) inhibitors have reported a
reduced risk of Alzheimer's disease (AD). Nevertheless, the effect of RAS inhibitor type and …

Some studies suggest that angiotensin II type 1 receptor blockers (ARBs) may protect
against memory decline more than angiotensin-converting enzyme inhibitors (ACE-Is), but …

We previously reported that angiotensin converting enzyme inhibitors (ACEIs) decrease the
rate of cognitive decline in elderly patients with hypertension, but their impact on patients …

Objective The effect of angiotensin converting enzyme (ACE) inhibitors on Alzheimer
disease (AD) remains unclear, with conflicting results reported. We studied the interaction of …

Background Prior work suggests that some but not all antihypertensive treatments may
benefit cognition and risk for Alzheimer's disease, independent of stroke. Angiotensin II …

Background: Centrally acting angiotensin converting enzyme inhibitors (CACE-Is) are
associated with reduced rates of cognitive decline in patients with dementia. CACE-Is may …

A quantitative meta-analysis was performed to evaluate the association of renin-angiotensin
system blockade (RASB) use with the incidence of cognitive impairment of aging and …

Background: Previous studies found that antihypertensive medications (AHMs) acting on the
renin-angiotensin system had the potential to reduce the progression from mild cognitive …